Matar Michael A, Zohar Joseph, Kaplan Zeev, Cohen Hagit
Ministry of Health Mental Health Center, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Eur Neuropsychopharmacol. 2009 Apr;19(4):283-95. doi: 10.1016/j.euroneuro.2008.12.004. Epub 2009 Jan 23.
In light of clinical reports suggesting that early benzodiazepine administration interferes with long-term recovery from traumatic stress, a prospective animal model for PTSD was employed to assess the short- and long-term effects of a brief course of alprazolam following stress exposure.
Animals exposed to stress were treated either 1 h or 7 days later with alprazolam or vehicle for 3-days. Outcome measures included behavior in the elevated plus-maze (EPM) and acoustic startle response (ASR) tests 30 days after initial exposure and freezing behavior upon exposure to a trauma-cue on day 31. One group was repeatedly exposed to the triggering trauma shortly before and after treatment and assessed as above. Circulating corticosterone levels were assessed 4 h after initiation of alprazolam and post-treatment. Pre-set cut-off behavioral criteria classified exposed animals according to their EPM and ASR response-patterns into 'extreme', 'minimal,' or 'partial' behavioral response for analysis of prevalence rates.
Immediate alprazolam treatment was effective in alleviating anxiety at day 4. No observable anxiolytic effects remained at day 30. Immediate alprazolam also resulted in significantly greater freezing response to trauma-cue exposure and in extreme responses to double-exposure. Corticosterone levels were significantly suppressed by alprazolam during treatment and rebounded after cessation.
A brief course of alprazolam in the immediate aftermath of stress-exposure is associated with less favorable responses to additional stress-exposure later on. Alprazolam was associated with a significant attenuation of the HPA-response, suggesting a possible link between initial HPA-axis response disruption and the subsequent unfavorable outcomes.
鉴于临床报告表明早期使用苯二氮䓬类药物会干扰创伤应激的长期恢复,我们采用了一种创伤后应激障碍(PTSD)的前瞻性动物模型,以评估应激暴露后短期和长期使用阿普唑仑的效果。
应激暴露后的动物在1小时或7天后接受阿普唑仑或赋形剂治疗,为期3天。结果指标包括初次暴露后30天在高架十字迷宫(EPM)中的行为和听觉惊吓反应(ASR)测试,以及在第31天暴露于创伤线索时的僵住行为。一组在治疗前后不久反复暴露于触发创伤,并按上述方法进行评估。在开始使用阿普唑仑后4小时和治疗后评估循环皮质酮水平。预先设定的行为标准根据暴露动物在EPM和ASR反应模式将其分为“极端”、“最小”或“部分”行为反应,以分析患病率。
立即给予阿普唑仑治疗在第4天可有效减轻焦虑。在第30天未观察到明显的抗焦虑作用。立即给予阿普唑仑还导致对创伤线索暴露的僵住反应明显增强,以及对双重暴露的极端反应。在治疗期间,阿普唑仑可显著抑制皮质酮水平,停药后皮质酮水平反弹。
应激暴露后立即短期使用阿普唑仑与随后对额外应激暴露的反应较差有关。阿普唑仑与下丘脑-垂体-肾上腺(HPA)反应的显著减弱有关,提示初始HPA轴反应破坏与随后不良结果之间可能存在联系。